Art of Prevention: The Importance of Dermatologic Care When Using Aromatase Inhibitors

    July 2021 in “ International Journal of Women’s Dermatology ”
    Sara Behbahani, Amaris Geisler, Avani Kolla … Miriam Keltz Pomeranz
    Studysummary In this review, the authors detailed various dermatologic adverse events associated with aromatase inhibitors in postmenopausal women and discussed strategies to potentially prevent these events, aiming to minimize interruptions in breast cancer treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails American Journal of Clinical Dermatology · 2018
    2. Hair Disorders in Patients with Cancer Journal of The American Academy of Dermatology · 2018
    3. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer JAMA Dermatology · 2018
    4. Minoxidil for Endocrine Therapy–Induced Alopecia in Women With Breast Cancer—Saint Agatha’s Blessing? JAMA Dermatology · 2018
    5. Management of Hair Loss Associated with Endocrine Therapy in Patients with Breast Cancer: An Overview SpringerPlus · 2016
    6. Aromatase Inhibitors Induce Male Pattern Hair Loss in Women Annals of Oncology · 2013
    7. Alopecia in a Premenopausal Breast Cancer Woman Treated with Letrozole and Triptorelin Annals of Oncology · 2003